This Funding Opportunity Announcement (FOA) intends to support investigators who have interest and capability to join efforts for the discovery of in vivo chemical probes for novel brain targets. It is expected that applicants will have in hand the starting compounds (“validated hits”) for chemical optimization and bioassays for testing new analog compounds.
Through this FOA, NIH wishes to stimulate research in 1) discovery and development of novel, small molecules for their potential use in understanding biological processes relevant to the missions of NIMH, NEI, NIAAA, NIDA, NIA and/or NIDCD and 2) discovery and/or validation of novel, biological targets that will inform studies of brain disease mechanisms. Emphasis will be placed on projects that provide new insight into important disease-related biological targets and biological processes.
Although this funding opportunity uses the R01 grant mechanism, it runs in parallel with a program announcement of identical scientific scope, PAR-17-335, which uses the exploratory/developmental (R21) grant mechanism.
- R01 Deadlines: Feb. 5, Jun. 5, Oct. 5
- R21 Deadlines: Feb. 16, Jun. 16, Oct. 16
- AIDS Deadlines: Jan. 7, May 7, Sep. 7
PAR-17-336 Expiration Date September 8, 2020